LH

Business Context and Reporting Period

Company: Laboratory Corporation of America Holdings (LabCorp)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2007
Business Overview: LabCorp operates as a leading provider of diagnostic testing services. The reporting period covers the third quarter and first nine months of fiscal year 2007. The company continues to expand its managed care relationships, notably with UnitedHealthcare, while executing cost-reduction initiatives and facility consolidations.

Key Financial Metrics

Note: Gross margins were 41.4% for Q3 2007 and 42.0% for Q3 2006. Operating margins were 17.5% for Q3 2007 and 19.3% for Q3 2006.

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 12.2% in Q3 and 13.8% for the nine-month period compared to 2006. Growth was driven by an 11.9% increase in accession volume (primarily from Managed Care) and a 0.3% price increase in Q3.
• Restructuring Charges: The company recorded significant restructuring charges of $31.3 million in Q3 2007 (totaling $38.3 million for the nine months). This compares to only $1.0 million in the same periods of 2006. Charges included $18.0 million in severance for approximately 1,130 employees and $7.8 million for facility closures.
• Cost of Sales: Cost of sales increased 14.0% in Q3, outpacing revenue growth. This was attributed to the rollout of patient service centers, shifts in test mix, and providing specimen collection supplies to new clients.
• Acquisitions: The company acquired 14 medical reference laboratories for approximately $145 million in cash during the first nine months of 2007.
• Debt Structure: Short-term borrowings increased to $661.8 million from $554.4 million at year-end 2006, primarily due to $100 million drawn on the revolving credit facility.

Guidance, Outlook, and Risks

• Capital Expenditures: Management expects full-year 2007 capital expenditures to be between $130 million and $140 million, supporting strategic initiatives in managed care and IT connectivity.
• UnitedHealthcare Contract: Under a 10-year agreement, LabCorp committed to reimburse UnitedHealthcare up to $200 million for transition costs over the first three years. Approximately $27.9 million was billed in the first nine months of 2007. Management estimates the total reimbursement will be approximately 40% less than the contractual limit.
• Share Repurchases: The company repurchased $520.8 million of common stock (7.3 million shares) in the first nine months of 2007. As of September 30, 2007, approximately $329.2 million remained authorized for repurchase.
• Debt Refinancing: On October 26, 2007 (post-period), the company entered into new $1 billion credit facilities (a $500 million revolving facility and a $500 million term loan) to replace the previous facility.
• Risks: Key risks include changes in federal/state reimbursement policies, regulatory investigations (Medicare/Medicaid), loss of managed care contracts (e.g., loss of Aetna contract effective July 1, 2007), and the ability to integrate acquisitions effectively.

Investor Verification Checklist

• Restructuring Impact: Verify the realization of the projected $60 million in annual cost reductions from the Q3 2007 restructuring actions.
• UnitedHealthcare Transition Costs: Monitor the actual total reimbursement paid to UnitedHealthcare against the management estimate of being 40% below the $200 million cap.
• Debt Covenants: Confirm continued compliance with financial covenants under the new $1 billion credit facility entered into in October 2007.
• Accounts Receivable: Review the $118.2 million increase in accounts receivable during the nine-month period and its impact on Days Sales Outstanding (DSO).
• Legal Contingencies: Track the status of the patent infringement case with Competitive Technologies, Inc., where a $7.8 million judgment was paid but the case was remanded for further proceedings.